Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma.

Altered levels of amyloid β-protein precursor (AβPP) and/or amyloid beta (Aβ) are characteristic of several neurological disorders including Alzheimer's disease (AD), Down syndrome (DS), Fragile X syndrome (FXS), Parkinson's disease (PD), autism and epilepsy. Thus, these proteins could serve as valuable blood-based biomarkers for assessing disease severity and pharmacological efficacy. We have observed significant differences in Aβ1-42 levels in human plasma dependent on the anticoagulant utilized during blood collection. Our data suggests that anticoagulants alter AβPP processing and that care needs to be used in comparing published studies that have not utilized the same blood collection methodology.

[1]  D. Geschwind,et al.  Biochemical markers in persons with preclinical familial Alzheimer disease , 2008, Neurology.

[2]  R. Mayeux,et al.  Elevated plasma beta-amyloid peptide Abeta(42) levels, incident dementia, and mortality in Down syndrome. , 2007, Archives of neurology.

[3]  J. Malter,et al.  FMRP Mediates mGluR5-Dependent Translation of Amyloid Precursor Protein , 2007, PLoS biology.

[4]  M. Farlow,et al.  High Levels of Alzheimer Beta-Amyloid Precursor Protein (APP) in Children With Severely Autistic Behavior and Aggression , 2006, Journal of child neurology.

[5]  M. Inglese,et al.  Plasma levels of amyloid β-protein 42 are increased in women with mild cognitive impairment , 2004, Neurology.

[6]  Laurie A. Miller,et al.  Senile plaques in temporal lobe epilepsy , 1994, Acta Neuropathologica.

[7]  H. Wiśniewski,et al.  Alzheimer's disease in Down's syndrome , 1985, Neurology.

[8]  A. Fagan,et al.  Performance characteristics of plasma amyloid-beta 40 and 42 assays. , 2009, Journal of Alzheimer's disease : JAD.

[9]  C. Sanberg,et al.  Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. , 2008, International journal of clinical and experimental medicine.

[10]  A. Hofman,et al.  Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. , 2006, The Lancet. Neurology.

[11]  J. Malter,et al.  Extracellular-regulated kinase controls beta-amyloid precursor protein mRNA decay. , 2001, Brain research. Molecular brain research.

[12]  H. Wiśniewski,et al.  Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease , 2000 .